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Abstract Atypical hemolytic uremic syndrome (aHUS) is
a heterogeneous disease that is caused by defective
complement regulation in over 50% of cases. Mutations
have been identified in genes encoding both complement
regulators [complement factor H (CFH), complement factor
I (CFI), complement factor H-related proteins (CFHR), and
membrane cofactor protein (MCP)], as well as complement
activators [complement factor B (CFB) and C3]. More
recently, mutations have also been identified in thrombo-
modulin (THBD), an anticoagulant glycoprotein that plays
a role in the inactivation of C3a and C5a. Inhibitory
autoantibodies to CFH account for an additional 5–10% of
cases and can occur in isolation or in association with
mutations in CFH, CFI, CFHR 1, 3, 4, and MCP. Plasma
therapies are considered the mainstay of therapy in aHUS
secondary to defective complement regulation and may be
administered as plasma infusions or plasma exchange.
However, in certain cases, despite initiation of plasma
therapy, renal function continues to deteriorate with
progression to end-stage renal disease and renal transplan-
tation. Recently, eculizumab, a humanized monoclonal
antibody against C5, has been described as an effective
therapeutic strategy in the management of refractory aHUS
that has failed to respond to plasma therapy. Clinical trials
are now underway to further evaluate the efficacy of
eculizumab in the management of both plasma-sensitive
and plasma-resistant aHUS.
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Introduction
As the most common cause of acute renal failure in
childhood, hemolytic uremic syndrome (HUS) is a clinical
entity that arises as a result of a systemic thrombotic
microangiopathy (TMA). Characterized by the triad of a
microangiopathic hemolytic anemia, thrombocytopenia,
and acute renal failure, over 90% of childhood HUS results
from infection with Shiga-toxin producing Escherichia coli
(STEC) and ‘typically’ presents with a diarrheal prodrome
[1, 2]. Accounting for the remaining 10% of childhood
HUS, atypical HUS (aHUS) is a heterogeneous disease that
is associated with defective regulation of the alternative
complement pathway in over 50% of cases (Table 1)[ 1, 3–
6]. Mutations have been identified in genes encoding both
complement regulators [complement factor H (CFH) [7–
13], complement factor I (CFI) [14–24], complement factor
H-related proteins (CFHR 1/3 and CFHR 1/4A) [1, 25, 26]
and membrane cofactor protein (MCP) [27–31] in addition
to complement activators [complement factor B (CFB) [18,
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DOI 10.1007/s00467-010-1556-432, 33] and C3 [34, 35]. An additional 6–10% of aHUS
cases are associated with inhibitory CFH autoantibodies
that block the C-terminal recognition domain of CFH and
reduce CFH binding to C3 [25, 36]. The majority of
patients with CFH autoantibodies are also deficient for
CFHR1, which shares structural and functional similarities
to CFH and inhibits C5 convertase activity and thereby
terminal complex formation [26, 37]. More recently, CFH
autoantibodies have also been associated with mutations in
other complement regulators such as CFH, CFI, and CD46
(MCP) [38]. Furthermore, mutations in thrombomodulin
(THBD), an anticoagulant glycoprotein which regulates C3b
inactivation by factor I were recently identified in a further
6–10% of aHUS cases, thereby confirming previous associ-
ations between the coagulation cascade and complement
regulation [39, 40]. A remaining 40% of aHUS cases are
currently unaccounted for, and thereby necessitate investiga-
tion of additional susceptibility factors and demand further
explanation of phenotypic presentation in pedigrees demon-
strating incomplete penetrance. For a more detailed overview
of the genetic etiology of aHUS, the reader is referred to
several excellent reviews on this topic [5, 41–43].
In contrast to Stx-HUS, aHUS is associated with a poor
long-term prognosis (Table 2), may be familial [44], and is
characterized by frequent relapses [45] and progression to
end-stage renal disease (ESRD) in at least 50% of cases [4].
Disease recurrence following isolated renal transplantation
is high and has been reported to occur in up to 30–100% of
aHUS patients depending on the underlying complement
defect [27, 46, 47]. Increasingly, it is recognized that a
combination of mutations in genes encoding complement
components, single-nucleotide polymorphisms (SNPs) and
risk haplotypes must be present for aHUS to manifest in an
individual [38, 48, 49]. Consequently, determination of the
optimum therapeutic strategy can be challenging. The aim
of this review is to provide an overview of the published
experience of plasma therapy in aHUS associated with
defective complement regulation. A second aim of this
review is to highlight emerging evidence for a role for new
agents that target the terminal complement cascade and may
be the treatment of choice in cases associated with multiple
complement defects.
Overview of complement activation and regulation
Complement activation is a central component of the innate
immune system, playing an important role in target
opsonization, leucocyte recruitment, and cell lysis [50–
53]. Complement can be activated by three major path-
ways: the alternative pathway (AP) is spontaneously and
continuously active, the classical pathway (CP) is activated
when antibodies bind their cognate antigen or the lectin
pathway (LP), which is activated by the binding of
mannose-binding lectin (MBL) to mannose residues on
the surface of microorganisms. Complement activation
occurs sequentially, beginning with initiation of activation,
followed by C3 convertase activation and amplification, C5
convertase activation, which leads to assembly of the lytic
membrane attack complex (MAC). The critical initiating
step in complement activation is the cleavage of C3 to
generate C3b and the formation of C3-convertase, which
are protease complexes (AP, C3bBb; CP/LP, C2AC4b)
(Fig. 1). Further amplification of activated C3b occurs
when AP C3bBb is generated by convertase-generated C3b.
Binding of C3b to the C3-convertase generates the C5-
1. Infection-induced HUS
(a) Shiga and vero-cytotoxin (Shiga-like) producing bacteria
(b) Streptococcus pneumonia
2. Defective Complement Regulation
(a) Genetic defects of complement regulation e.g. factor H deficiency
(b) Acquired defects of complement regulation e.g. factor H autoantibodies
3. Defective ADAMTS13 function
(a) Genetic deficiency of ADAMTS13
(b) Acquired inhibition e.g. ADAMTS13 autoantibodies
4. Genetic deficiency of thrombomodulin
5. Defective cobalamine metabolism
6. Miscellaneous
a. Quinine-induced HUS (antibodies to platelet glycoproteins)
b. HIV
c. Pregnancy
d. Calcineurin-induced HUS
e. Malignancy
f. Systemic lupus erythematosus and antiphospholipid syndrome
Table 1 Etiology and classifi-
cation of hemolytic uremic
syndrome (HUS)
42 Pediatr Nephrol (2011) 26:41–57convertase with the capacity to bind and cleave C5,
initiating formation of the MAC.
Under normal circumstances, circulatory C3 activation is
low and is a tightly regulated process under the control of
four major classes of regulatory proteins: fluid phase
complement regulators, membrane-bound complement reg-
ulators, complement receptors, and surface-bound comple-
ment regulators [43] (Fig. 1). Regulation occurs at multiple
steps including the inactivation of C3b or C4b, the
dissociation of the C3/C5 convertase, or the inhibition
MAC formation. Fluid-phase regulators circulate in plasma
and include the alternative pathway regulators, complement
factor H (CFH), and factor H-like protein (FHL), glyco-
proteins that are synthesized in the liver. FHL-1 is an
alternative splice product of CFH [52]. CFH regulates
complement activation by at least three different mecha-
nisms (Fig. 1). Firstly, CFH binds to CFI, a serine protease
that mediates the proteolytic cleavage of the α-chain of C3b
resulting in the formation of iC3b (co-factor activity) [54].
Following further cleavage by CFI, iC3b forms the C3dg
and C3c fragments using the membrane-bound complement
receptor 1 (CR1 or CD35) [55, 56]. A second function of
CFH includes the inhibition of the interaction between C3b
and CFB and thereby blocks the formation of the C3bBb
convertase complex (decay-accelerating activity). Further-
more, CFH promotes the dissociation of C3 convertase
once they have formed (decay-accelerating activity). Bind-
ing of CFH by its C-terminus to sialic acid, glycosamino-
glycans, or sulfated polysaccharides (heparin) increases the
affinity of CFH for surface-bound C3b. Additional regula-
tion is further achieved by the presence of five structurally
related proteins to CFH (CFHR1-5) and are all composed
of short consensus repeats (SCRs) that share different
degrees of identity with SCRs in CFH [57]. A regulatory
function for CFHR1-5 proteins is suggested by their ability
to bind C3b. Recent work has shown that CFHR1 blocks
C5 convertase activity and interferes with C5b surface
deposition and MAC formation [26, 58]. Similar to CFH,
CFHR proteins are also synthesized in the liver but are
present in much lower concentrations compared to CFH.
In addition to regulation within the fluid phase, regulation
also occurs at the level of the cell membrane. Several
membrane-bound proteins have been shown to regulate
complement and include complement receptors 1 and 2,
complement decay accelerating factor (DAF), membrane-
bound cofactor protein (MCP; CD46), protectin (CD59),
and complement receptor of the immunoglobulin super-
family (CRIg) (Fig. 1). Membrane-bound factors control
the three major complement activation pathways and
Table 2 Summary of clinical outcome in patients with aHUS
Genetic defect Frequency Response to short-term plasma therapy Long-term outcome Outcome after kidney
transplantation
CFH 20–30% Rate of remission: 60%
(dose- and timing-dependent)
Rate of death or ESRD: 70–80% Rate of recurrence:
80–90%
CFI 4–10% Rate of remission: 30–40% Rate of death or ESRD: 60–80% Rate of recurrence:
80–90%
CFHR1 & 3 with CFH
autoantibodies
6% Rate of remission: 70–80% Rate of death or ESRD: 30–40% Rate of recurrence: 20%
MCP 10–15% No indication for therapy Rate of ESRD or death: <20% Rate of recurrence:
15–20%
CFB 1–2% Rate of remission: 30% Rate of death or ESRD: 70% Recurrence in one case
C3 5–10% Rate of remission: 40–50% Rate of death or ESRD: 60% Rate of recurrence:
40–50%
THBD 5% Rate of remission: 60% Rate of death or ESRD: 60% Recurrence in one case
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Fig. 1 Activation and regulation of the alternative complement
pathway. Complement factor H binds to the endothelial cell surface,
C3b, and with membrane co-factor protein (MCP), acts as a co-factor
for cleavage of C3b. This process is mediated by complement factor I.
This presents the formation of C3bBb complex. Dissociation of the C3
convertase is also mediated by factor H. Thrombomodulin enhances
factor-I- mediated cleavage of C3b in the presence of factor H and
promotes activation of TAFIa (thrombin activatable fibrinolysis
inhibitor), which degrades C3a and C5a. Ab antibody; CFB
complement factor B; CFH complement factor H; CFI complement
factor I; TM thrombomodulin; MCP membrane cofactor protein;
TAFIa thrombin activatable fibrinolysis inhibitor; Thn thrombin
Pediatr Nephrol (2011) 26:41–57 43inactivate both C3 and C4. Fluid-phase regulators, on the
other hand, are more specific and regulate either the
alternative, classical, or the lectin pathways and act almost
exclusively on either C3 or C4.
Investigation of aHUS during disease flares
Management of an aHUS crisis first begins with recogni-
tion and diagnosis. Clinically, HUS presents with a triad of
microangiopathic hemolytic anemia (fragmented erythro-
cytes with low haptoglobin levels), thrombocytopenia, and
acute renal failure. As set out in detail in the report
published in 2006 by the European Study Group for HUS,
the classification of HUS, thrombotic thrombocytopenic
purpura (TTP) and related disorders is summarized in
Table 1. An aHUS crisis occurring secondary to defective
complement regulation should be considered if the follow-
ing features are present: presentation before 6 months of
age, insidious onset, previous episode of HUS, previous
unexplained anemia, asynchronous family history of HUS
or HUS post-transplantation of any organ, as recently
described in the ‘Guidelines for the Investigation and Initial
Therapy of Diarrhoea-Negative Hemolytic Uremic Syn-
drome’ published by the European Study Group for HUS
[3]. Investigation for enterohemorrhagic Escherichia coli
should still be undertaken in the context of atypical
features, as unusual presentations have been known to
occur [59].
If a patient is suspected of having aHUS, then
measurement of plasma complement C3, C4, CFH, CFH
autoantibodies, CFI and CFB levels, and surface expression
of MCP (CD46) on mononuclear leucocytes by FACS
should be undertaken (Table 3). Furthermore, genetic
mutation analysis for the susceptibility genes, CFH, CFI,
CFHR1-5, CFB, CD46, and C3 should also be undertaken.
If a patient has had a blood transfusion, then it is advisable
to wait for 2 weeks before undertaking any mutational
analysis. Details of the laboratories offering specialized
investigation can be found on the following Web site: http://
espn.cardiff.ac.uk.
It is important to note that while low levels of C3 may
indicate complement dysregulation, there are occasions
when C3 levels are normal [60]. Activation of the
alternative pathway may still be a feature and measurement
of serum MAC and iC3b may prove to be a more useful
indicator of alternative pathway activity with sMAC
indicating the degree of activation of the terminal comple-
ment cascade and iC3b indicating the degree of inactivation
of C3b. Elevated C3d levels are also an indicator of
alternative pathway activation. Where C3 levels are normal,
genetic investigation is still clearly warranted in such cases
of aHUS [41, 60]. Furthermore, recent evidence has
demonstrated that mutations in several complement genes
can manifest in any one individual and therefore, mutation
screening should be undertaken for all predisposing genes if
possible. A summary of the known disease-causing
mutations can be found on the following Web site: www.
fh-hus.org and have been reviewed in detail elsewhere in
this series. Careful consideration should also be given to
other causes of aHUS, such as disorders of cobalamin
metabolism as well as ADAMTS13 activity (a disintegrin
and metalloprotease with thrombospondin motifs). While
beyond the scope of this article, the reader is referred to
Table 3 Diagnostic tests for complement activation in aHUS
Complement
proteins
Plasma concentration Technique Interpretation
C3 660–1,250 mg/l Nephelometry Hypocomplementemia is strongly suggestive
of alternative pathway activation in aHUS
APH50 50–125% Radio immunodiffusion Elevation suggests activation of the
alternative pathway
CH100 311–827 Units Radio immunodiffusion
C3dg/C3d < 40 mU/l Double-decker rocket
immunoelectrophoresis, using anti-C3c and
anti-C3d antibodies
CFB 93–380 mg/l Nephelometry Low CFB is suggestive of alternative
pathway activation in aHUS
CFH 330–680 mg/l ELISA CFH level less than 60% suggests deficiency
CFI 40–80 mg/l ELISA CFI level less than 60% suggests deficiency
Anti-CFH
autoantibody
Negligible ELISA Autoantibodies against the C-terminus are
thought to be pathogenic
MCP Mean fluorescence intensity Flow cytometry analysis with anti-MCP
phycoerythrin (PE)-conjugated antibodies
Homozygous deficiency is associated with no
MCP expression. MFI is 50% in
heterozygous individuals
44 Pediatr Nephrol (2011) 26:41–57other reviews on these disorders regarding diagnosis and
management [61, 62].
Plasma therapy in aHUS associated with complement
dysregulation
Plasma therapy is considered the first-line therapy for
aHUS [3, 6, 41, 63, 64]. While there have been no
controlled clinical studies, the introduction of plasma
therapy into the management of aHUS was associated with
a decrease in mortality from 50 to 25% [65, 66]. Plasma-
based therapies may be classified as plasma infusion (PI) or
plasma exchange (PEX). Plasma infusion is thought to
replace defective complement components and regulators
with functional proteins [67, 68]. Plasma exchange offers
the additional advantage of removal of mutant CFH, CFI,
CFB, C3, and CFH autoantibodies while restoring func-
tional complement regulators.
Given the emerging evidence for the existence of a
combination of complement defects and risk haplotypes in
disease manifestation, it is no longer sufficient to consider
the management of aHUS as simply a matter of replacing a
single deficient factor by PI or removal of a mutant factor
by PEX. As a result, the European Working Group on HUS
has recently published consensus guidelines with the aim of
establishing a standardized approach to the initial manage-
ment of aHUS and thereafter with a view to auditing this
approach again in 3 years [3]. As there have been no
randomized controlled clinical trials investigating the
efficacy of either PI or PEX in the management of aHUS,
the published guidelines are expert consensus opinions
based on combined personal experiences and published
case reports.
Guidelines suggest that plasmapheresis should be com-
menced within 24 h of initial presentation along with
supportive treatment (transfusion, dialysis, antihypertensive
therapy). However, in clinical practice, this may not always
be possible due to the time that it may take to rule out
infection with for EHEC. Neurological symptoms in HUS
can be a consequence of many factors such as cerebral
microangiopathy with ischemia and infarction, hyperten-
sion, and cerebral edema arising from metabolic disturban-
ces. The presence of these symptoms indicates a
progressive disease process and following correction of
hypertension and metabolic disturbances with dialysis,
plasmapheresis should be instituted promptly in those cases
suspected of having aHUS. Initially, 1.5 times the expected
plasma volume should be exchanged or a plasma infusion
of 20–30 ml/kg of body weight should be administered [3].
Replacement with whole plasma fraction such as virus-
inactivated pooled plasma or individual units of fresh
frozen plasma (FFP) from screened donors is recommended
[69]. PEX may be achieved by plasma filtration or via a
centrifugal separator, according to local practice and
expertise. Daily PEX is recommended for the initial 5 days
followed by five sessions per week for the next 2 weeks
and then tapered to three sessions per week for the
subsequent 2 weeks [3].
Following initiation of plasmapheresis, it is advisable to
monitor the full blood count, electrolytes, and serum
creatinine daily to determine whether the therapy has made
any impact on the degree of hemolysis and renal dysfunc-
tion. Similarly, it may also be helpful, in those cases
presenting with low C3 levels, to measure daily C3 levels
throughout plasmapheresis to help determine the optimal
therapeutic regime in individual cases for the management
of subsequent disease flares. The current guidelines suggest
that remission has been achieved if platelet counts are
sustained >150×10
9/l for 2 weeks and there has been no
hemolysis as determined by the presence of fragmented red
cells, elevated lactate dehydrogenase, and low haptoglobins
[3]. Recurrence of thrombocytopenia and hemolysis after
2 weeks of recovery of both parameters signifies a relapse
and reinstitution of plasmapheresis is recommended if
previously successful. Furthermore, for auditing purposes,
it is recommended that the renal function be graded as
normal [glomerular filtration rate (GFR) ≥80 ml/min/
1.73 m
2 as determined by the Schwartz formula or by a
formal clearance assay], renal impairment whereby plasma
creatinine level is elevated for age or GFR <80 ml/min/
1.73 m
2 or renal failure (requiring dialysis). Furthermore,
the presence of proteinuria and hypertension (expressed as
a centile based on age and gender) including number of
antihypertensive agents should be recorded.
Following a period of 3 years, the European Study
Group on aHUS aims to audit the proportion of cases
investigated and the resultant yield from the proposed
investigations to determine what proportion were treated
according to the guidelines and the proportion that were
withdrawn or did not meet the criteria for treatment
according to the guidelines. Importantly, the objective of
the recommended guidelines also propose to determine the
proportion of patients entering hematological remission
based on the recommended therapy schedule for the first
month and those that have preserved or loss of renal
function by the end of the first month.
Summary of reported therapy response of individual
complement regulatory defects
With the advent of extended mutational analysis in aHUS
patients, it is now very clear that disease manifestation is
more frequently associated with a combination of risk
factors that not only includes mutations in key complement
Pediatr Nephrol (2011) 26:41–57 45components and regulators but also risk haplotypes and
SNPs in other complement components. In the ensuing
text, we review the published experience of either PI or
PEX in cases that have previously been reported as defects
in a single component. Response to plasma therapy in
relation to underlying genetic defects should be interpreted
with caution as it is possible that further defects would be
found in such patients if they were to undergo further
genetic screening. Therefore, the objective of the ensuing
text is to highlight the outcome of individual cases based
on the reported therapeutic regimen employed and thereby
demonstrate the divergent outcomes even amongst those
cases that appeared to have similar underlying genetic
defects.
CFH
Deficiency of CFH may be either quantitative or functional.
A quantitative deficiency is defined as CFH plasma levels
below half of normal [9]. Complete deficiency is extremely
rare and is defined by the total absence or severe reduction
in CFH levels. To date, 34 CFH-deficient patients have
been described from 16 families [9, 70–81]. Renal disease
has been reported in 28 of these 33 cases, of whom 16
developed aHUS [67, 72, 76–79, 82–85]. The clinical
presentation of those with complete CFH deficiency and
their complement profile, plasma therapy regimen, and
outcome are summarized in Supplementary Table 1.I f
plasma therapy such as PI with FFP is initiated early in the
course of the disease when the serum creatinine level is
normal or only slightly elevated, then it may be possible to
preserve renal function for a number of months or years
[86]. However, as there may be more than one defect
present, recommendations now advocate for PEX as the
initial treatment regimen with the additional advantage of
removal of mutant proteins while restoring functional
proteins. Functional CFH deficiency is more common than
complete CFH deficiency and is associated with a normal
CFH level. While mutations have been found throughout
the gene, over 80% occur within the region that encodes the
C-terminal domain of the protein and results in reduced
binding of C3b and to polyanions leading to impaired
function of CFH. For patients, with a functional deficiency
of CFH, the response to plasma exchange with FFP
replacement has been shown to be effective [87–91]
(Supplementary Table 2). As mutations of CFH are
heterogeneous, a strategy of intensive and prophylactic
PEX may not be necessary in all patients with CFH
mutations and therapy should be tailored according to
individual patient response. Furthermore, resistance to
long-term plasma therapy has been reported in patients
[88, 92]. Although the underlying mechanisms for the
development of resistance require investigation, a plausible
reason may be the development of autoantibodies to CFH
or other complement proteins for which assays are not
readily available.
Purified CFH concentrates
As the strategy of prophylactic PEX is expensive, neces-
sitates creation of an arteriovenous fistula, central venous
access, and implies life-long regular treatment in a hospital,
the development of a purified human plasma-derived CFH
concentrate may provide sufficient CFH in a small volume
to replace PEX and thereby reduce the risks associated with
central venous access and volume overload. Whether it will
suffice to administer it alone or in combination with PEX
will have to be determined in the future. Development of
such a concentrate is currently being undertaken by the
Laboratoire Français du Fractionnement et des Biotechnol-
ogies (details can be found at the Web site: www.emea.
europa.eu/pdfs/human/comp/opnion/52123506en.pdf).
Management of CFH autoantibodies during disease flares
Recent studies have suggested a pathogenic role for CFH
autoantibodies in the development of aHUS [25, 93, 94].
Functional studies have demonstrated that CFH autoanti-
bodies bind to the C-terminus of CFH and thereby inhibit
C3b binding, leading to enhanced complement activation
and red cell hemolysis [95]. Furthermore, deficiency of
the complement regulatory proteins, CFHR1 and CFHR1/
3, has also been described in patients with CFH-
autoantibody associated aHUS (Supplementary Table 3)
[25, 38, 96–98].
Current recommendations propose that a trial of PEX
therapy is warranted in an attempt to remove CFH
autoantibodies [21, 99]. PEX provides an excess of CFH
that may saturate and neutralize the autoantibody activity
and partially restore functional CFH circulating levels,
while removing the autoantibody from the circulation [5].
In the pre-transplantation setting, intravenous immunoglob-
ulin (IVIG) and rituximab (the anti-CD20 [67] antibody)
have been utilized with efficacy in preventing recurrence
post-transplantation and is described in detail in the section
entitled 'Transplantation in aHUS'.
CFI
Mutations in CFI account for around 10% of aHUS cases
[14] and similarly to CFH, result in either a quantitative or
functional deficiency of CFI protein [22]. A poor prognosis
exists for aHUS associated with CFI mutations with over
50% of reported cases progressing to ESRD following
initial presentation. Approximately 40% of CFI mutations
result in low levels of CFI [33]. Therefore, replacement
46 Pediatr Nephrol (2011) 26:41–57with plasma theoretically should restore deficient CFI in
patients who have only CFI mutations. However, as
outlined in Supplementary Table 4, the response to either
PI alone or PEX is often inadequate and this may be due to
the occurrence of concomitant complement defects or risk
haplotypes that were not detected at the time of reporting.
CFB
Patients carrying CFB gain-of-function mutations develop
aHUS as a result of decreased decay of the C3bBb
convertase [32]. Of four patients in whom details of
treatment has been reported, plasma therapy was adminis-
tered to three patients, with one patient receiving PEX only,
one patient receiving PI only, and one patient receiving a
combination of both. Disease progressed in all patients
despite plasma therapy with four patients progressing to
ESRD. The fourth patient, at the time of reporting, had
moderate renal insufficiency but had not received plasma
therapy. An additional patient who also carries a CFI
mutation experienced immediate disease recurrence in the
renal allograft following transplantation and despite treat-
ment with intravenous immunoglobulin (IVIG), ESRD has
progressed in the allograft almost 5 years later [47]. Patients
carrying gain-of-function CFB mutations are likely to
require very large amounts of FFP and very frequent PEX
in order to overcome the overproduction and resistance to
decay of the alternative pathway C3 convertase to C3bBb.
This will need to be confirmed by serial measurements of
complement during therapy in future studies.
MCP
Patients carrying MCP (CD46) mutations tend to recover
completely from aHUS relapses [24, 46, 47]. None of the
children reported so far develop ESRD at 1 year from initial
presentation while 86% remain dialysis-free in the long
term [24, 46, 47]. Evidence from individual case reports
[20] in addition to the reports from the Italian [46] and
French series [24] suggest that plasma therapy is unlikely to
be of therapeutic benefit in CD46 mutation-associated
aHUS. In the French series, favorable outcome occurred
in eight (89%) of nine episodes that were treated with
plasma therapy and 15 (88%) of 17 untreated episodes [24].
Caprioli et al. reported in the Italian series that complete or
partial remission (defined by recovery of hematological
parameters with persistence of renal dysfunction) was
achieved in 91% of plasma-treated episodes but also in
100% of the non-treated episodes [46]. However, in those
patients who did not recover spontaneously, it was not
possible to conclude that plasma therapy failed because it
was not adequately administered. Furthermore, a recently
reported fifth case by Davin et al. was initially treated with
daily PEX and recovered normal renal function [100].
However, recurrence of aHUS over the subsequent 4 years
was associated with a progressive decline towards ESRD
despite continuous prophylactic PEX. The lack of a
response in aHUS patients carrying MCP mutations is likely
owing to the fact that MCP is a membrane-bound protein
and its role is limited to endothelial cells, and as a result, is
not associated with systemic complement dysregulation.
Transplantation in aHUS
Outcome
Recurrence post-transplantation has been reported in three
retrospective cohorts of aHUS patients with defective
complement regulation [24, 46, 101]. Within the larger
cohorts, mutations in CFH, CFI, or MCP were reported in
around 50% of aHUS patients and post-transplant recur-
rence was reported in 33% [24], 37% [46], and 60% [101]
of grafts.
Transplantation in patients carrying CFH mutations is
particularly unfavorable with an almost 80–100% recur-
rence rate reported, depending on the degree of quantitative
deficiency of CFH and the concurrence of other comple-
ment defects. In one series, 74% of CFH mutated patients
had HUS recurrence from 2 days to 22 months after
transplantation; 93% (13/14) of recurrences induced graft
loss, most often (85.7% of recurrences) within the year after
recurrence. Only one of the 15 grafts with recurrence was
functioning at 6 years of follow-up [101]. Similarly poor
outcomes have been reported by the UK (78%) [48], and
Italian Registries (83%) [46]. For those with CFI mutations,
a similar rate of recurrence has been reported with 11 of 12
grafts failing in eight recipients due to disease recurrence
[15, 20, 36, 47, 102]. While recurrence data for CFB and
C3 mutations are also emerging [90, 103], conclusions
regarding appropriate therapeutic strategies cannot be made
until more cases are reported.
Role of combined liver-kidney transplantation
Combined liver-kidney transplantation has recently been
advocated for patients with CFH and CFI mutations as CFH
and CFI are circulating factors synthesized by the liver [6,
47, 104–106]. Justification for liver transplantation comes
from the fact that mutant CFH or CFI will continue to be
produced by the liver in those who receive a renal
transplant only and therefore, recipient mutant CFH or
CFI may still not regulate complement activation suffi-
ciently in the donor renal allograft, thereby leaving it
susceptible to disease recurrence. Initial reports of ortho-
topic liver transplantation in aHUS were disappointing with
Pediatr Nephrol (2011) 26:41–57 47the first CFH-deficient recipient experiencing acute hepatic
failure during the liver transplant [12]. A second liver was
transplanted at day 26, resulting in aHUS remission, the
patient later developed neurological sequelae from severe
hepatic encephalopathy [107]. A 2½-year-old was the
second recipient who received a liver transplant from his
father following severe, recurrent hemolytic/thrombocyto-
penic episodes but had preserved renal function. Following
transplantation, the patient suffered fatal liver failure
immediately following transplantation following a period
of graft hypoperfusion that led to complement activation
and microvascular thrombosis and infarction in the liver
allograft. He died 10 months later from lymphoproliferative
disease and recurrent infections associated with features of
HUS [108]. However, despite the poor outcome for both of
these cases, normalization of CFH levels post-
transplantation was demonstrated for the first patient and
recurrence was avoided in the second, thereby suggesting
that combined liver-kidney transplantation may be an
effective strategy for preventing disease recurrence in
patients with aHUS. Subsequently, a modified approach
was employed whereby pre-transplantation PEX was
administered to remove mutant CFH in addition to peri-
transplantation PI after hepatectomy and before donor liver
implantation, which led to increased bioavailability of CFH
during acquisition of allograft liver function [106]. Further-
more, low-dose enoxaparin and aspirin were employed to
counteract the enhanced thrombogenicity of the allograft
endothelium [106]. Furthermore, a role for isolated liver
transplantation may also be considered in patients who have
frequent relapses but stable renal function. While a paucity
of data exists, preliminary guidelines have been proposed
based on experience drawn from about one dozen liver-
kidney transplants for aHUS worldwide over the past
decade. Successful liver-kidney transplants have been
undertaken in four centers worldwide and should be
undertaken in an experienced center given the high rate of
postoperative complications. It is likely that plasma require-
ments will vary between individuals to control complement
activation which can be exacerbated on reperfusion of the
transplanted liver. The amount of required plasma may also
depend on how long it takes for the transplanted liver to
establish its synthetic function and the rate of synthesis of
complement regulatory proteins. Patients with surgical
complications leading to prolonged warm ischemia and
delayed liver graft function will probably require more
plasma over an extended period.
Renal transplantation in CFH autoantibody-associated
aHUS
A paucity of literature exists as to the success of isolated
renal transplantation of patients with CFH autoantibodies.
Recently, Kwon and colleagues reported successful renal
transplantation in a 10-year-old girl with CFH
autoantibody-associated aHUS [99]. Prior to transplanta-
tion, therapy consisted of prednisolone, azathioprine, and
PEX in an attempt to decrease the CFH autoantibody titre.
A decrease in CFH autoantibody titres following six
sessions of PEX (50 ml/kg/session over 15 days) was
observed. On cessation of PEX, CFH autoantibody titers
rose again within a month, but on initiation of a second
course of PEX, subsequently decreased again, thereby
suggesting a potential beneficial role for PEX in removing
CFH autoantibodies [99]. No recurrence of disease oc-
curred following an exchange program of 50 ml/kg/session
with FFP substitution immediately prior to surgery and
continued daily during the first week following transplan-
tation with subsequent tapering over the following 4 months
[99]. HUS did not recur in the following 2 years post-
transplantation. Further reports of successful renal trans-
plantation in CFH-autoantibody-associated aHUS without
recurrence have recently emerged and without adjuvant
rituximab [38, 98]. Induction of immunosuppression with
basiliximab, the IL2 receptor antagonist, in addition to
high-dose corticosteroids and mycophenolate mofetil was
utilized as a steroid-sparing agent and no disease recur-
rence, thereby suggesting that this immunosuppressive
regimen may be efficacious in certain cases of CFH-
autoantibody-associated aHUS.
Living-related organ donation
Familial cases of aHUS associated with complement
defects have been reported [30, 46, 109] and therefore,
following presentation of the index case, it would be
prudent to discuss the possibility of disease manifestation in
other family members. In our opinion, urinalysis and blood
pressure monitoring should be undertaken in all family
members on at least an annual basis. If proteinuria or
hypertension became evident, then further investigation of
renal function, complement profile and genetic testing for
complement defects may be warranted. In the event of
transplantation, living-related organ donation is contra-
indicated in patients with CFH, CFI, CFB, and C3
mutations owing to a significant recurrence risk in the
renal allograft [6, 47]. Owing to the incomplete penetrance
of HUS associated with complement defects in family
members, the genetic variability within family members in
addition to a number of SNPs, living-related donation is not
without risk. Furthermore, the remaining kidney in the
donor may also be susceptible to disease manifestation
where it has been previously reported that four donors
developed HUS in their native kidneys following donation
[47, 110]. If living-related donation is the only possible
option, complete genotyping of all known complement
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the absence of a mutation or risk haplotype, the donor must
be informed that there remains a possibility that he might
have some unknown risk factor of developing HUS after
kidney donation [47].
Therapies affecting the terminal complement cascade
Eculizumab
Emerging evidence has shown that patients presenting with
aHUS can have a constellation of genetic defects that result
in over-activation of the alternative complement cascade
[66, 103]. Such patients represent a significant therapeutic
challenge and, as a result, disease flares may be best treated
with agents that target the membrane attack complex
(MAC) composed of C5b-9, the final effector pathway of
complement activation. Eculizumab, a humanized mono-
clonal antibody against C5, has recently been shown to be
an effective treatment in aHUS [100, 103, 111–113].
Initially, eculizumab was employed in the therapy of
patients with paroxysmal nocturnal hemoglobinuria where
it was shown to markedly reduce intravascular hemolysis,
the need for transfusion, and patient fatigue [114, 115]. It
has also been shown to be effective in patients with
rheumatoid arthritis, systemic lupus erythematosus, myo-
cardial infarction, membranous nephritis, and those who
have undergone coronary artery bypass surgery [116].
Biochemically, eculizumab is an IgG immunoglobulin
comprised of human constant regions and murine comple-
mentarity determining regions grafted onto human frame-
work light- and heavy-chain variable regions. Eculizumab
is composed of two 448-amino-acid heavy chains and two
214-amino-acid light chains and has a molecular weight of
approximately 148 kDa. Eculizumab does not inhibit C5
activity in animal sera but does bind to human tissues,
including smooth and striated muscle as well as renal
proximal epithelium. In animal studies, eculizumab was
found to cross the placental barrier and show fetal
morbidity and mortality [117]. Details can be found on
the following Web site http://www.emea.europa.eu/human
docs/Humans/EPAR/soliris/soliris.htm.
Mechanism of action
Complement C5 is split by C5 convertase into C5a and C5b
(Fig. 2a). C5a increases the permeability of blood vessels
and attracts inflammatory cells by chemotaxis. C5b binds to
other complement components (C6, C7, and C8). The C5b-
8 complex is expanded with C9 to form the MAC. MAC
binds and permeabilizes bacterial walls (e.g. Neisseria),
thereby killing the microorganism. Eculizumab is a long-
acting humanized monoclonal antibody targeted against
complement C5 (Fig. 2b)[ 118]. The plasma half-life is
estimated to be about 11 days (personal communication
with Alexion Pharmaceuticals). It inhibits the cleavage of
C5 into C5a and C5b and hence inhibits deployment of the
terminal complement system including the formation of
MAC.
Efficacy of eculizumab in aHUS
Five aHUS patients treated with eculizumab have been
reported in the literature thus far [100, 103, 111–113]. Two
patients have been treated in the pre-transplantation setting
[111, 112] while the remaining three have received therapy
post-transplantation [100, 103]. In addition to the afore-
mentioned five cases reported in the literature, an additional
14 patients have been treated with eculizumab, ten of whom
achieved stable remission [4]. Of those reported and
receiving treatment in the pre-transplantation setting, the
first report was that of an 18-month-old male infant with
congenital aHUS who had frequently relapsing aHUS
[111]. Following the development of resistance to plasma
therapy, a fourth relapse at 18 months of age was treated
with weekly eculizumab at 300 mg doses weekly for
Fig. 2 Site of action of eculizumab. a Complement C5 is split by C5
convertase into C5a and C5b. C5a increases the permeability of blood
vessels and attracts inflammatory cells by chemotaxis. C5b binds to
other complement components (C6, C7, and C8). The C5b-8 complex
is expanded with C9 to form the MAC. MAC binds and permeabilizes
bacterial walls (e.g. Neisseria), thereby killing the microorganism. b
Eculizumab is a long-acting humanized monoclonal antibody targeted
against complement C5. It inhibits the cleavage of C5 into C5a and
C5b and hence inhibits deployment of the terminal complement
system including the formation of MAC
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2 weeks thereafter. An improvement in the hematological
and biochemical parameters was noted within 48 h of
initiation of therapy and subsequently, plasma therapy was
discontinued within the first week of eculizumab therapy.
While a genetic defect in complement regulation was not
identified in this infant and the hematological parameters
improved just prior to the initiation of therapy, additional
evidence for the beneficial effects of eculizumab in acute
aHUS were recently reported in an adolescent with
unclassified aHUS [63]. PEX was initially effective in
facilitating the temporary improvement of renal function.
On tapering the plasma exchanges to three times per week,
aHUS activity progressed to ESRD. After 12 weeks,
eculizumab was initiated and was effective in terminating
the microangiopathic hemolytic process in two aHUS
relapses [112]. However, after normalization of comple-
ment activity, aHUS recurred and ultimately led to anuric
ESRD. A similarly beneficial experience has been reported
in three renal transplant patients who experienced aHUS
recurrence [100, 103, 113]. The first was a 30-year-old
female with a combined CFH mutation (Y475S) and
CFHR1 deletion [113]. She was treated with 600 mg of
eculizumab after her renal function deteriorated following
failure of PEX initiated for recurrence of aHUS in a second
allograft. She had lost her first allograft due to disease
recurrence that was resistant to plasma 7 years earlier.
Following commencement of eculizumab, the transplant
function recovered with resolution of the total complement
hemolytic activity and 8 months later, the patient’s renal
graft function is stable at the time of reporting [113]. Since
this initial report, a further two cases have been reported. A
17-year-old girl with aHUS associated with a CFH
mutation (S1191L) was plasma-dependent and successfully
treated with eculizumab following the development of
severe allergic reactions to plasma after her third allograft
[20]. The fifth reported case treated with eculizumab is that
of a 42-year-old woman with a heterozygous gain-of-
function mutation (R570Q) in the C3 gene [103]. Following
aHUS recurrence in her second renal allograft, she
underwent intensive PEX to which she responded. Howev-
er, PEX was discontinued as she experienced side-effects of
diarrhea and fatigue. Treatment with eculizumab was
initiated 4 days after the final session. She received four
doses of eculizumab, 900 mg IVevery week, followed by a
maintenance dose of 1,200 mg every 2 weeks. After
7 months of eculizumab treatment, and without concomi-
tant plasmapheresis, schistocytes decreased to 0.5%, hap-
toglobin increased to within normal limits, creatinine levels
stabilized, and no further episodes of diarrhea were
reported. The need for blood transfusions was significantly
reduced and they were stopped 4 months after continued
eculizumab treatment. Therefore, clearly there is a role in
the event of recurrence of aHUS. Whether a role exists for
prophylactic eculizumab in the prevention of recurrence
and thereafter its safety will have to be determined in future
studies. Duration of therapy should be determined by the
maintenance of remission of hemolysis and thrombocyto-
penia. In the current trials involving adolescents and adults,
eculizumab will be provided for 6 months. Enrollment has
just been completed and the results of the study are
anticipated later this year. It is likely that the required
duration of therapy will vary from patient to patient
depending on the underlying complement defects.
Dosage and administration
Eculizumab is administered as an intravenous infusion and
pharmacodynamic assays demonstrate that inhibition of C5
sufficient to prevent hemolysis occurs at eculizumab
plasma concentrations in excess of 35 µg/ml [119].
Eculizumab (Soliris©, Alexion Pharmaceuticals) is admin-
istered as an infusion in adults at a dose of 600 mg over 25
to 45 min with therapeutic doses of the drug achieved
within 1 h of infusion. The frequency of administration can
be weekly and the dose further increased to 900 mg in
adults in the fifth week. Thereafter, maintenance doses can
be administered on an alternate weekly basis at 900 mg.
Currently, there are no dosage recommendations for
children under 12 years of age. However, with the advent
of trials due to commence later this year, in younger
children at acute presentation and in the pre-transplantation
setting, guidelines for appropriate dosage for this age-group
may be further developed.
Adverse effects
The main side-effects of therapy are an increased
susceptibility to meningococcal infection as a result of
MAC inhibition. MAC plays a crucial role in eliminating
neisserial infections and defects in components of MAC
are strongly associated with recurrent bacterial infections
involving encapsulated Gram-positive or Gram-negative
organisms such as neisserial and pneumococcal infec-
tions. It is advisable that patients carry a special card
stating the risks and symptoms of susceptible infections
such as Neisseria meningitidis when they are receiving
treatment with eculizumab. Patients should be vaccinated
against Neisseria meningitidis at least 2 weeks before
treatment with eculizumab and revaccination is also
recommended according to current guidelines. While
antibodies will be generated following immunization, they
will be of reduced efficacy as partly their action will rely
on the terminal complement pathway. As a result,
prophylactic antibiotics should also be considered for the
duration of the treatment.
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Owing to the reported benefits of eculizumab in individual
cases of aHUS, its efficacy is currently being evaluated in a
number of controlled clinical trials (ClinicalTrials.gov
numbers NCT00844545, NCT00844428, NCT008838513,
NCT00844844). Of these, one trial is an open-label
controlled trial of eculizumab in adolescent patients (aged
12–18 years) with plasma therapy-sensitive aHUS
(NCT00844428). This study is currently in phase II with
recruitment just recently completed. The treatment period is
for 6 months with analysis of results expected by the end of
this year. Eligibility criteria can be found on the Web site:
http://clinicaltrials.gov/ct2/show/NCT00844428. A second
trial is determining the efficacy in adolescent patients with
plasma therapy-resistant aHUS (NCT00844844). Resistance
to plasma therapy is defined as a decrease in platelet count
despite at least four plasma therapy (PT) treatments in the
first week immediately prior to screening (screening platelet
count, 150×10
9/l and at least 25% lower than remission
platelet count or if remission counts not available, screening
platelet count <75×10
9/l). Details of related adult studies can
be found on the following Web site: http://clinicaltrials.gov/
ct2/show/NCT008838513 (adult patients with therapy-
sensitive aHUS) and http://clinicaltrials.gov/ct2/show/
NCT00844545 (adult patients with therapy-resistant aHUS).
Primary outcome measures include the assessment of the
efficacy of eculizumab in reducing TMA while secondary
outcome measures include additional efficacy endpoints
related to manifestations of TMA, pharmacokinetics and
pharmacodynamics of eculizumab in patients with aHUS,
overall safety, and tolerability of eculizumab. Inclusion and
exclusion criteria are as outlined in Tables 4 and 5.I ti s
hoped that further trials addressing the efficacy and
Table 4 Criteria for assessment of the efficacy of eculizumab in adolescents with plasma therapy-sensitive aHUS (NCT00844428)
Inclusion criteria
1. Male or female patients from 12 and up to 18 years of age who have been diagnosed with atypical hemolytic uremic syndrome (aHUS)
2. Patients must be receiving plasma therapy (PT) for aHUS
3. Platelet count pre-PT baseline set-point (collected immediately prior to the qualifying PT episode) is within 75% of the average of the pre-PT
platelet counts collected at screening and during the observation period
4. Diagnosis of aHUS
5. Lactate dehydrogenase (LDH) level ≥upper limit of normal (ULN)
6. Creatinine level ≥ULN for age
7. Female patients of childbearing potential must be practicing an effective, reliable, and medically acceptable contraceptive regimen during the
entire duration of the study, including the follow-up period
8. Patient's parents/legal guardian must be willing and able to give written informed consent and patient must be willing to give written informed
assent
9. Able and willing to comply with study procedures
Exclusion criteria
1. ADAMTS13 inhibitor or deficiency (i.e. ADAMTS13 activity <5%) as measured at the screening visit
2. Malignancy
3. Typical HUS (Shiga toxin +)
4. Known HIV infection
5. Identified drug exposure-related HUS
6. Infection-related HUS
7. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the investigator, confounds an accurate
diagnosis of aHUS or impedes the ability to manage the aHUS disease
8. Pregnancy or lactation
9. Unresolved meningococcal disease
10. Known systemic lupus erythematosus (SLE) or antiphospholipid antibody positivity or syndrome
11. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or
confound the outcome of the study
12. Patients receiving intravenous immunoglobulin (IVIG) or rituximab therapy
13. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors, or FK506 inhibitors are excluded unless: (1) part of
a post-transplant anti-rejection regime, (2) patient has confirmed anti-CFH antibody requiring immunosuppressive therapy, and (3) dose of
such medications have been unchanged for at least 4 weeks prior to the screening period
14. Patients receiving erythrocyte stimulating agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period
15. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior
to screening and throughout the entire trial
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patients less than 12 years of age in the near future both in
the setting of acute presentation as well as the peri-
transplantation period.
Conclusions
Atypical hemolytic uremic syndrome is a heterogeneous
disease in which defective complement regulation currently
accounts for around 50% of cases. Defects in more than one
complement regulator are frequently present in many aHUS
cases and thereby pose a significant therapeutic challenge.
As a result, targeting the final effector pathway in comple-
ment activation may provide a more effective strategy in
modifying disease progression. Recent reports propose an
efficacious role for eculizumab in the management of aHUS.
Results of the recently completed trial in adolescents are
eagerly awaited. Enrollment of childhood cases of aHUS in a
much anticipated trial is expected to commence later this
year. Within the peri-transplantation setting, it will be
important to determine the role of prophylactic eculizumab
in the prevention of recurrence of aHUS.
Multiple-choice questions
(Answers appear following the reference list)
1. Atypical hemolytic uremic syndrome is caused by
regulatory defects in:
a. The mannose-binding lectin pathway
b. The alternative complement pathway
Table 5 Criteria for assessment of the efficacy of eculizumab in adolescents with plasma therapy-resistant aHUS (NCT00844844)
Inclusion criteria
1. Male or female patients up to 18 years of age who have been diagnosed with atypical hemolytic uremic syndrome (aHUS)
2. Decrease in platelet count despite at least four plasma therapy (PT) treatments in the first week immediately prior to screening
Screening platelet count, 150×10
9/l and at least 25% lower than remission platelet count or
if remission counts not available, screening platelet count <75×10
9/l
3. Diagnosis of aHUS
4. Lactate dehydrogenase (LDH) level ≥ULN
5. Creatinine level ≥ULN for age
6. Female patients of childbearing potential must be practicing an effective, reliable, and medically acceptable contraceptive regimen during the
entire duration of the study, including the follow-up period
7. Patient's parents/legal guardian must be willing and able to give written informed consent and patient must be willing to give written informed
assent
8. Able and willing to comply with study procedures
Exclusion criteria
1. ADAMTS13 inhibitor or deficiency (i.e. ADAMTS13 activity <5%) as measured at the screening visit
2. Malignancy
3. Typical HUS (Shiga toxin +)
4. Known HIV infection
5. Identified drug exposure-related HUS
6. Infection-related HUS
7. Renal function status requiring chronic dialysis
8. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the investigator, confounds an accurate
diagnosis of aHUS or impedes the ability to manage the aHUS disease
9. Pregnancy or lactation
10. Unresolved meningococcal disease
11. Known systemic lupus erythematosus (SLE) or antiphospholipid antibody positivity or syndrome
12. Any medical or psychological condition that, in the opinion of the investigator, could increase the patient's risk by participating in the study or
confound the outcome of the study
13. Patients receiving IVIG or rituximab therapy
14. Patients receiving other immunosuppressive therapies such as steroids, mTOR inhibitors, or FK506 inhibitors are excluded unless: (1) part of
a post-transplant anti-rejection regime, (2) patient has confirmed anti-CFH antibody requiring immunosuppressive therapy, and (3) dose of
such medications have been unchanged for at least 4 weeks prior to the screening period
15. Patients receiving erythrocyte stimulating agents (ESAs) unless already on a stable dose for at least 4 weeks prior to the screening period
16. Participation in any other investigational drug trial or exposure to other investigational agent, device, or procedures beginning 4 weeks prior
to screening and throughout the entire trial
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d. T-cell function
2. Which of the following is NOT a feature of comple-
ment activation?
a. Low C3 levels
b. High C3 levels
c. High C3d levels
d. High iC3b levels
3. Which of the following defects in complement
regulation have NOT been described in atypical
hemolytic uremic syndrome?
a. Factor H deficiency
b. Factor B deficiency
c. Factor I deficiency
d. C3 deficiency
4. Which of the following is NOT a function of factor H?
a. Acts as co-factor to factor I in the proteolytic
cleavage of C3b to iC3b
b. Binds to C3b and blocks the formation of the C3
convertases
c. Factor H inhibits the dissociation of the C3
convertases
d. Factor H binds sialic acid
5. Which of the following statements regarding factor I
function is INCORRECT?
a. Factor I is a serine protease
b. Factor I inactivates C3b via the cleavage of the C3
α-chain
c. Factor I inactivates C3b via the cleavage of the C3
β-chain
d. Factor I cleaves iC3b into C3c and C3dg using
CR1 as a cofactor
6. Renal thrombotic microangiopathy is a feature of
atypical hemolytic uremic syndrome and is associated
with the following:
a. Mutations in the N-terminus of factor H
b. Mutations in the C-terminus of factor H
c. Inactivation of the C5-9 terminal attack complex
d. Inactivation of the iC3b complex
7. Current treatment modalities for atypical hemolytic
uremic syndrome DO NOT include:
a. Plasmapheresis
b. Plasma infusion
c. Factor Q concentrate
d. Rituximab
8. The half-life of circulating factor H is
a. 1 day
b. 6 days
c. 7 days
d. 10 days
9. Rituximab has been reported to be effective in the
peri-transplantation management of atypical hemolytic
uremic syndrome associated with the following defect
in complement regulation:
a. Factor I mutation
b. Factor H autoantibodies
c. Factor B mutation
d. Factor H mutation
10. Eculizumab has recently been reported to be effective
in acute aHUS. Which of the following is TRUE
regarding its mechanism of action?
a. Promotes cleavage of C3 to C3b
b. Promotes cleavage of C5 to C5b
c. Prevents cleavage of C5 to C5b
d. Promotes cleavage of iC3b to C3dg
11. Which of the following is NOT an inclusion criterion
for the current clinical trial of eculizumab in atypical
hemolytic uremic syndrome:
a. Adolescents aged 12–17 years of age
b. Adults >18 years of age
c. Children aged 2–12 years of age
d. Assured diagnosis of atypical hemolytic uremic
syndrome within 2 weeks of screening
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